NTLA Live signals | Maximize Profits with Getagraph.com

BUY 63547 min ago

@ $29.86

Issued: 11 Mar 2024 @ 11:11

Return: -28.99%

Previous signal: Mar 11 - 09:31

Previous signal: Sell

Return: -1.35 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 14:19):

Stats
Today's Volume	492 867
Average Volume	1.55M
Market Cap	2.04B
EPS	$0 ( 2024-02-22 )
Next earnings date	( $-1.340 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.91
ATR14	$0.0180 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Dube Michael P	Sell	0	Common Stock
2024-03-01	Sepp-lorenzino Laura	Buy	37 966	Common Stock
2024-03-01	Sepp-lorenzino Laura	Buy	54 794	Stock Option (right to buy)
2024-03-01	Basta James	Buy	32 394	Common Stock
2024-03-04	Basta James	Sell	2 297	Common Stock

INSIDER POWER
85.54
Last 100 transactions
Buy: 1 561 723 \| Sell: 123 854

Volume Correlation

Long: 0.09 (neutral)

Short: -0.37 (neutral)

Signal:(39.794) Neutral

Intellia Therapeutics Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Intellia Therapeutics Inc Correlation - Currency/Commodity

0.04
( neutral )

0.31
( neutral )

0.00
( neutral )

0.20
( neutral )

0.17
( neutral )

-0.75
( moderate negative )

Intellia Therapeutics Inc Financials

Annual	2023
Revenue:	$36.28M
Gross Profit:	$27.30M (75.26 %)
EPS:	$-5.42

Q4	2023
Revenue:	$-1.92M
Gross Profit:	$-4.38M (228.64 %)
EPS:	$-1.460

Q3	2023
Revenue:	$11.99M
Gross Profit:	$9.70M (80.90 %)
EPS:	$-1.380

Q2	2023
Revenue:	$13.59M
Gross Profit:	$11.42M (84.04 %)
EPS:	$-1.400

Financial Reports:

No articles found.

Intellia Therapeutics Inc

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.